LOGIN   |   JOIN
제목 [의학뉴스] FDA In Brief: FDA updates public information about known risk o…
조회수 1,807 등록일 2018-03-30
내용


16e5e4dc19c9917ea2c4a8256d0ef7f4_1522416

 

U.S. Food and Drug Administration| Mar 21, 2018

16e5e4dc19c9917ea2c4a8256d0ef7f4_1522416

 

 

"The FDA has been closely tracking the relationship between breast implants and a rare type of non-Hodgkin's lymphoma since we first identified this possible association. We’ve been working to gather additional information to better characterize and quantify the risk so that patients and providers can have more informed discussions about breast implants,” said Binita Ashar, M.D., director of the division of surgical devices in FDA’s Center for Devices and Radiological Health. “As part of that effort, we are working to update and enhance the information we have on this association, including updating the total number of known cases of BIA-ALCL and the lifetime risk of developing BIA-ALCL as reported in medical literature. We hope that this information prompts providers and patients to have important, informed conversations about breast implants and the risk of BIA-ALCL. At the same time, we remain committed to working in partnership with all stakeholders to continue to study, understand and provide updates about this important public health issue"

 

Today, the FDA is communicating updated information about its understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

The agency is providing an updated number of medical device reports (MDRs) (also known as adverse event reports) and medical literature estimates regarding risk reviewed by the agency since the last public update in March 2017. We are reporting that we are aware of 414 total cases of BIA-ALCL. Additionally, studies reported in medical literature estimate that the lifetime risk of developing BIA-ALCL for patients with textured breast implants ranges from 1 in 3,817 to 1 in 30,000.

The agency is also updating the content and format of the webpage for the agency’s breast implant post-approval studies to make current information about these important studies easier for patients to read and understand.

Today’s update does not change the agency’s recommendations regarding breast implants. Choosing to obtain a breast implant is a very personal decision that patients and their providers should make based on individual needs and with the most complete information about risks and benefits .

 

 

 The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 

 

 

16e5e4dc19c9917ea2c4a8256d0ef7f4_1522416

 

출처 : U.S. Food and Drug Administration
원문바로가기
: https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm602070.htm

 

 

16e5e4dc19c9917ea2c4a8256d0ef7f4_1522416

 

 

 

 

 

 

 

 


 

  • 목록
이용약관   |   개인정보처리방침   |   이메일문의   |   카카오톡문의

순천향대학교 서울병원  |  04401 서울시 용산구 대사관로 59  |  사업자등록번호 106 82 00610
순천향대학교 서울병원 콜센터 : 02-709-9000  |   이메일 : sim_hyungbo@naver.com  |   사이트 소유자 : 심형보